

**Date: 09th November, 2025**

To,
BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street - Fort,
Mumbai — 400 001.

Ref.: BSE Scrip Code - 539730**Subject: Revised Outcome of Board Meeting**

Dear Sir / Madam,

Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 we wish to inform you that the Board of Directors of the Company at its meeting held on Saturday, November 08th, 2025 has inter-alia, considered, adopted and approved following items of business:

1. In compliance to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Un-Audited Financial Results of the Company for the Quarter and Half-Year Ended 30th September, 2025 along with the Limited Review Report as issued by M/s. R.H. Nisar & Co, Statutory Auditors of the Company; copies of which are attached hereunder;

In furtherance to the intimation filed by the Company dated September 26, 2025 the trading window for trading in securities of the Company by insiders closed on October 01st, 2025 till the end of 48 hours after the declaration of outcome of the Board Meeting.

The Board Meeting commenced at 04.00 p.m. and concluded at 10:30 p.m.

Kindly oblige and take the same on your Records.

Thanking you,

FOR FREDUN PHARMACEUTICALS LIMITED

FREDUN NARIMAN MEDHORA
MANAGING DIRECTOR
DIN: 01745348



FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare

CIN No : L24239MH1987PLC043662



UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30.09.2025

PARTICULARS	Standalone					
	Quarter Ended			Half Year Ended		Year Ended
	Unaudited			Unaudited		Audited
	30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31.03.2025
	Rs. In Lakhs	Rs. In Lakhs	Rs. In Lakhs	Rs. In Lakhs	Rs. In Lakhs	Rs. In Lakhs
1 Income from Operations						
Net Sales / Income From Operation (Net of GST)	14358.53	11940.29	10689.19	26298.82	18442.77	45170.62
2 Other Operating Income	170.61	45.21	46.16	215.82	173.66	456.20
3 Total income from operations (net)	14529.14	11985.50	10735.35	26514.64	18616.43	45626.82
4 Expenses						
a) Cost of Material Consumed	9925.75	9032.62	6739.80	18958.37	12490.47	32188.90
b) Cost of Material Consumed for R & D	118.32	75.47	51.23	193.79	88.91	209.34
c) Other R & D Expenses	0.00	0.00	0.00	0.00	0.00	0.00
d) Changes in inventories of finished goods, work-in-progress and stock in trade	441.29	(666.14)	787.11	(224.85)	754.43	605.00
e) Manufacturing & Service Cost	366.13	363.91	496.17	730.04	823.85	1755.54
f) Finance Costs	773.13	653.17	531.21	1426.30	922.45	2237.66
g) Employees benefits expenses	829.88	763.39	358.46	1593.27	668.40	2223.12
h) Depreciation and amortisation expenses	159.80	141.91	106.32	301.71	211.04	444.91
i) Other Expenses	614.25	717.13	907.45	1331.38	1347.38	3135.27
Total expenses	13228.55	11081.46	9977.75	24310.01	17306.93	42799.74
5 Profit/(Loss) from ordinary activities before exceptional items & tax (3-4)	1300.59	904.04	757.60	2204.63	1309.50	2827.08
6 Exceptional items / Prior Period Item	0.00	0.00	0.00	0.00	0.00	0.00
7 Profit/(Loss) from ordinary activities before tax (5-6)	1300.59	904.04	757.60	2204.63	1309.50	2827.08
8 Tax Expenses	327.36	227.46	330.27	554.82	469.18	746.32
9 Profit/(Loss) from continuing operations	973.23	676.58	427.33	1649.81	840.32	2080.76
10 Profit/(Loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
11 Tax Expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
12 Profit/(Loss) from discontinued operations after tax	0.00	0.00	0.00	0.00	0.00	0.00
13 Profit/ (Loss) for the period	973.23	676.58	427.33	1649.81	840.32	2080.76
14 Other comprehensive Income						
A (i) Items that will not be re-classified to profit/ loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be re-classified to profit/ loss	0.00	0.00	0.00	0.00	0.00	0.00
B (i) Re measurement of post - employment benefit obligations	0.00	0.00	0.00	0.00		(34.35)
C (i) Items that will be re-classified to profit / loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will be re-classified to profit/ loss	0.00	0.00	0.00	0.00	0.00	0.00
Total Comprehensive Income for the year	973.23	676.58	427.33	1649.81	840.32	2046.41
15 Paid up Equity Share Capital (Face Value of Rs-10/- ea	472.17	472.17	472.17	472.17	472.17	472.17
16 Reserves excluding Revaluation Reserves	0.00	0.00	0.00	0.00	0.00	0.00
17 Earning per Share (EPS) (before & after extra ordinary items)						
- Basic/ Diluted Earning Per Share (Rs.)	20.61	14.33	9.05	34.94	17.80	44.83
A						
1) Public Shareholding						
Number of shares	2411277	2411277	2411277	2411277	2411277	2411277
Percentage of shareholding	51.07%	51.07%	50.84%	51.07%	50.84%	51.07%
2) Promoters and promotor group shareholding						
a) Pledged/Encumbered						
- Number of shares	-	-	-	-	-	-
- Percentage of shares (as a % of total shareholding of Promoters and Prompter Group)	-	-	-	-	-	-
- Percentage of shares (as a % of total share capital of the Company)	-	-	-	-	-	-
b) Non-encumbered						
- Number of shares	2310385	2310385	2310385	2310385	2310385	2310385
- Percentage of shares (as a % of total shareholding of Promoters and Prompter Group)	100%	100%	100%	100%	100%	100%
- Percentage of shares (as a % of total share capital of the Company)	48.93%	48.93%	49.16%	48.93%	49.16%	48.93%

Registered Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.

Phone No.: 91-22- 4031 8111 Fax: 91-22-4031 8133

Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone No.: +917045957828, +917045957829, +917045957830, +917045956857

E-Mail: business@fredungroup.com Web: www.fredungroup.com



FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare



CIN No : L24239MH1987PLC043662

NOTES:-

- 1 The above unaudited financial results which are published in accordance with Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 08, 2025. These unaudited financial results have been prepared in accordance with recognition and measurement principles of Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and the other accounting principles generally accepted in India.
- 2 The above unaudited financial results for the quarter ended September 30, 2025 are prepared in compliance with the Ind AS which have been subjected to a limited review by the statutory auditors of the Company. The statutory auditors, Rakesh Nisar & Co have issued limited review reports with unmodified conclusion on the standalone and consolidated unaudited financial results.
- 3 As the Company's business activity falls within a single operating segment viz "Pharmaceutical and Healthcare", no segment
- 4 The figures for the quarter ended Sept 30, 2025 are the balancing figures between audited figures in respect of the full financial year and the published year to date unaudited figures upto the third quarter of the previous financial year.
- 5 The figures for the earlier periods have been regrouped/ reclassified wherever necessary to make them comparable with those of the current
- 6 The above results were reviewed and recommended by the Audit Committee, for approval by the Board, at its meeting held on November 08, 2025 and were approved and taken on record at the meeting of the Board of Directors of the company held on that date

PLACE: MUMBAI

DATE : 08th November , 2025

FOR FREDUN PHARMACEUTICALS LIMITED

Dr. (Mrs) DAULAT N. MEDHORA
Chair Person & Joint Managing Director
DIN :01745277



Registered Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.

Phone No.: 91-22- 4031 8111 **Fax:** 91-22-4031 8133

Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone No.: +917045957828, +917045957829, +917045957830, +917045956857

E-Mail: business@fredungroup.com **Web:** www.fredungroup.com

FREDUN PHARMACEUTICALS LIMITED			
Standalone Balance Sheet for the Half year Ended 30 September, 2025 (Rs. in Lacs..)			
		As at 30 September, 2025	As at 31 March, 2025
I	ASSETS		
	NON-CURRENT ASSETS		
a)	Property, Plant and Equipment	6,503.38	5,213.97
b)	Capital Work-in-Progress	-	-
c)	Other Intangible Assets	43.99	42.72
d)	Financial assets		
	i) Investments	92.73	76.33
	ii) Loans	-	-
	iii) Other Financial Assets	551.69	379.69
e)	Other Non-current Assets	634.19	198.99
	Total non - current assets	7,825.98	5,911.70
	CURRENT ASSETS		
a)	Inventories	22,530.80	23,988.89
b)	Financial Assets		
	i) Investments	75.00	75.00
	ii) Trade and other receivables	6,684.51	17,712.08
	iii) Cash and Cash Equivalents	207.25	22.97
	iv) Bank Balance other than (iii) above	587.82	458.63
	iv) Loans	79.98	46.99
	v) Other Financial Assets	7,644.59	120.27
c)	Other Current Assets	772.69	328.64
	Total current assets	38,582.63	42,753.46
	TOTAL ASSETS	46,408.60	48,665.16
II	EQUITY AND LIABILITIES		
	EQUITY		
a)	Equity share capital	472.17	472.17
b)	Other equity	15,284.68	13,667.93
	Total Equity	15,756.85	14,140.10
	LIABILITIES		
	Non-Current Liabilities		
a)	Financial liabilities		
	i) Borrowings	3,022.57	961.30
b)	Provisions	380.50	383.29
c)	Other non - current liabilities	-	-
d)	Deferred Tax Liability	448.40	448.40
	Total non current - liabilities	3,851.47	1,792.99
	Current Liabilities		
a)	Financial liabilities		
	i) Borrowings	14,045.13	15,679.36
	ii) Trade and other payable	9,941.96	14,475.80
	iii) Other financial liabilities	35.80	5.10
b)	Provisions		
c)	Other current liabilities	1,476.25	1,860.23
d)	Current tax liabilities (net)	1,301.14	711.58
	Total current liabilities	26,800.28	32,732.07
	TOTAL EQUITY & LIABILITIES	46,408.60	48,665.16

For and on behalf of the Board of Directors of Fredun Pharmaceuticals Limited

CIN No - L24239MH1987PLC043662
For Fredun Pharmaceuticals Limited



Dr. (Mrs) Daulat N. Medhora
Joint Managing Director
DIN : 01745277

MR. Fredun N. Medhora
Managing Director & CFO
DIN : 01745348

Place - Mumbai
Date :- 08.11.2025

FREDUN PHARMACEUTICALS LIMITED				
Standalone Statement of Profit and Loss for the Half year Ended 30 September, 2025			(Rs. In Lacs.)	
		As at 30 September, 2025	As at 31 March, 2025	
I	Revenue			
	Revenue from Operations	26,298.82	45,170.62	
	Other Operating Revenue	56.73	211.12	
	Other income	159.10	245.08	
	Total Income	26,514.65	45,626.83	
II	Expenses			
	Cost of materials consumed	18,958.38	32,188.89	
	Cost of materials consumed for R & D	193.80	209.34	
	Changes in inventories of raw materials, packing materials, stock in trade and wip	-224.86	605.00	
	Manufacturing & Service Cost	730.04	1,755.54	
	Employee benefit Exp.	1,593.27	2,223.12	
	Finance Cost	1,426.30	2,237.66	
	Depreciation and amortisation expense	301.71	444.91	
	Operating and other expenses	1,331.39	3,120.27	
	Payment to Auditors	-	15.00	
	Impairment loss / (reversal)			
	Total Expenses	24,310.02	42,799.74	
III	Profit before exceptional items and tax	2,204.62	2,827.08	
	Exceptional Items	-	-	
IV	Profit before tax from continuing operations	2,204.62	2,827.08	
V	Tax Expenses:			
	Current Tax	554.82	711.58	
	Deferred Tax	-	34.75	
VI	Profit for the year from continuing operations	1,649.80	2,080.76	
VII	Profit before tax from discontinued operations	-	-	
VIII	Tax expenses of discontinued operations	-	-	
IX	Profit for the year from discontinued operations	-	-	
X	Net Profit for the year	1,649.80	2,080.76	
XI	Other Comprehensive Income			
A	Items that will not be classified to profit and loss			
	i) Re measurement of post - employment benefit obligations	-	-34.35	
	ii) Income tax related to items that will not be reclassified to profit and loss	-	-	
B	Items that will be reclassified to profit and loss	-	-	
XII	Total Comprehensive Income for the year	1,649.80	2,046.41	
XIII	Earning per equity share (Face value of Rs. 10/- each)			
	Earning per equity share of continuing operations	34.94	44.83	
	Basic and diluted (in Rs.)			
	Earning per equity share of discontinued operations			
	Basic EPS (in Rs.) of continuing and discontinued operations	34.94	44.83	
	Diluted Basic EPS (in Rs.) of continuing and discontinued operations	34.94	44.83	

Place - Mumbai
Date :- 08.11.2025



For and on behalf of the Board of Directors of
CIN No - L24239MH1987PLC043662
For Fredun Pharmaceuticals Limited

Dr. (Mrs) Daulat N. Medhora
Joint Managing Director
DIN : 01745277

MR. Fredun N. Medhora
Managing Director & CFO
DIN :01745348

FREDUN PHARMACEUTICALS LIMITED

STANDALONE CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30th Sept, 2025

	<u>As at 30th Sept 2025</u>	<u>As at 30th Sept 2024</u>
	<u>(Amount in Lakhs)</u>	<u>(Amount in Lakhs)</u>
A) CASH FLOW FROM OPERATING ACTIVITIES:		
NET PROFIT AFTER TAXATION	1,649.80	840.32
<u>ADJUSTMENTS FOR :</u>		
DEPRECIATION	301.71	211.04
INTEREST PAID	1,426.30	922.45
INTEREST RECEIVED	4.49	2.10
CREDITORS WRITTEN BACK	0.00	-
	<u>1,732.50</u>	<u>1,135.60</u>
	3,382.30	1,975.92
<u>ADJUSTMENT TO OPERATING PROFIT</u>		
PRIOR PERIOD ADJUSTMENTS	-	-
DEFERRED TAX LIABILITY	- 34.08	-73.18
ADJUSTMENT FOR PROPOSED DIVIDEND TAX	-	-
ADJUSTMENT FOR TAX PROVISION	-	-
OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	<u>3,416.38</u>	<u>1,902.74</u>
<u>EFFECTS OF CHANGES IN WORKING CAPITAL ITEMS</u>		
<u>INCREASE / DECREASE IN :-</u>		
INVENTORY	-4,945.43	-1,609.27
INVESTMENTS	52.80	-47.00
TRADE RECEIVABLES	4,895.03	-6,931.11
LOANS & ADVANCES	-45.66	-12.95
OTHER CURRENT ASSETS	-748.13	2,431.63
OTHER FINANCIAL ASSETS	-6,777.03	-867.56
OTHER FINANCIAL ASSETS	-274.94	-202.33
TRADE PAYABLES	3,858.26	-1,927.50
OTHER CURRENT LIABILITIES	452.80	167.86
OTHER NON CURRENT ASSETS	-443.64	-3.49
OTHER NON CURRENT INVESTMENTS	-92.45	-
OTHER FINANCIAL LIABILITIES	31.97	-30.02
SHORT TERM PROVISION	-	-
PROVISION FOR TAX	309.86	353.88
RESERVES & SURPLUS	1,019.99	1,104.74
SHARE PREMIUM (RESERVES & SURPLUS)	<u>-2,706.57</u>	<u>-7,573.12</u>
	709.81	-5,670.38
<u>INCREASE / DECREASE IN :-</u>		
LONG TERM LOANS & ADVANCES	-	-
LONG TERM PROVISIONS	157.06	29.65
	<u>157.06</u>	<u>29.65</u>
NET CASH FLOW FROM OPERATING ACTIVITIES	<u>866.87</u>	<u>-5,640.73</u>
EFFECTS OF CHANGES IN NON CURRENT ITEMS		
OTHER NON CURRENT ASSETS		
NET ADJUSTED CASH FLOW FROM OPERATING ACTIVITIES	<u>866.87</u>	<u>-5,640.73</u>



[Handwritten signatures]

FREDUN PHARMACEUTICALS LIMITED



STANDALONE CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30th Sept, 2025

	As at 30th Sept 2025	As at 30th Sept 2024
	(Amount in Lakhs)	(Amount in Lakhs)
B) CASH FLOW FROM INVESTING ACTIVITIES		
PURCHASE OF FIXED ASSETS	-2,038.66	-805.26
SALE OF FIXED ASSETS	-	-
CAPITAL WORK IN PROGRESS	-	-
	-2,038.66	-805.26
	-1,171.79	-6,446.00
C) CASH FLOW FROM FINANCING ACTIVITIES		
INCREASE / DECREASE IN ISSUE OF SHARE CAPITAL	-	3.75
INCREASE / DECREASE IN LONG TERM BORROWINGS	1,924.96	-261.99
INCREASE / DECREASE IN SHORT TERM BORROWINGS	1,427.48	7,482.11
INTEREST RECEIVED	-4.49	-2.10
INTEREST PAID	-1,426.30	-922.45
CREDITORS WRITTEN BACK	-	-
	1,921.65	6,299.33
NET INCREASE / DECREASE IN CASH	749.86	-146.67
OPENING CASH & BANK BALANCE	45.21	191.88
CLOSING CASH & BANK BALANCE	795.07	45.21

For and on behalf of the Board of Directors of Fredun
Pharmaceuticals Limited

CIN No - L24239MH1987PLC043662

For Fredun Pharmaceuticals Limited

Dr. (Mrs) Daulat N. Medhora

Mr. Fredun N. Medhora

Joint Managing Director
DIN : 01745277

Managing Director & CFO
DIN : 01745348



Place : Mumbai
Date : 08.11.2025

Note:-

- The above Cash Flow Statement has been prepared under the indirect method set out in the Indian Accounting Standard (Ind AS) - 7 on "Statement of Cash Flow".
- 1 Direct taxes paid are treated as arising from operating activities and not bifurcated between investing and financing activities.
 - 2 Figures in Bracket sign indicate cash outflow.
 - 3 Previous year figures have been regrouped & recast, wherever necessary, to conform to the current year's classification.

R.H. Nisar & Co.
Chartered Accountant

501, Krushal Tower, M.G Road, Near Shoppers Stop, Chembur – 400089
Tel no: - 9867351724 Email - rakesh.nisar1@gmail.com

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Fredun Pharmaceuticals Limited,

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Fredun Pharmaceuticals Limited ('the Company') for the quarter ended 30th September 2025, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors on 08th November, 2025, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

R.H. Nisar & Co.

Chartered Accountant

501, Krushal Tower, M.G Road, Near Shoppers Stop, Chembur – 400089

Tel no: - 9867351724 Email - rakesh.nisar1@gmail.com

FOR R H NISAR & CO.

CHARTERED ACCOUNTANTS

FIRM'S REGISTRATION NUMBER: 120895W



RAKESH NISAR

PROPRIETOR

MEMBERSHIP NO. 103659

UDIN: 25103659BMODAC5190

PLACE: MUMBAI

DATE: 08.11.2025

FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare



CIN No: L24239MH1987PLC043662

UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30.09.2025

PARTICULARS	Consolidated					
	Quarter Ended			Half Year Ended		Year Ended
	Unaudited			Unaudited		Audited
	30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31.03.2025
	Rs. In Lakhs	Rs. In Lakhs	Rs. In Lakhs	Rs. In Lakhs	Rs. In Lakhs	Rs. In Lakhs
1 Income from Operations						
Net Sales /IncomeFrom Operation (Net of GST)	14358.53	11940.29	0.00	26298.82	0.00	45170.65
2 Other Operating Income	170.62	45.21	0.00	215.83	0.00	456.20
3 Total income from operations (net)	14529.15	11985.50	0.00	26514.65	0.00	45626.85
4 Expenses						
a) Cost of Material Consumed	9925.76	9032.62	0.00	18958.38	0.00	32188.90
b) Cost of Material Consumed for R & D	118.33	75.47	0.00	193.80	0.00	209.34
c) Other R & D Expenses	0.00	0.00	0.00	0.00	0.00	0.00
d) Changes in inventories of finished goods, work-in-progress and stock in trade	441.28	(666.14)	0.00	(224.86)	0.00	605.00
e) Manufacturing & Service Cost	366.13	363.91	0.00	730.04	0.00	1755.54
f) Finance Costs	773.13	653.17	0.00	1426.30	0.00	2237.66
g) Employess benefits expenses	829.88	763.39	0.00	1593.27	0.00	2223.12
h) Depreciation and amortisation expenses	189.31	141.91	0.00	331.22	0.00	503.95
i) Other Expenses	614.80	717.13	0.00	1331.93	0.00	3153.99
Total expenses	13258.62	11081.46	0.00	24340.08	0.00	42877.50
5 Profit/(Loss) from ordinary activities before exceptional items & tax (3-4)	1270.53	904.04	0.00	2174.57	0.00	2749.35
6 Exceptional items / Prior Period Item	0.00	0.00	0.00	0.00	0.00	0.00
7 Profit/(Loss) from ordinary activities before tax (5-6)	1270.53	904.04	0.00	2174.57	0.00	2749.35
8 Tax Expenses	327.36	227.46	0.00	554.82	0.00	775.42
9 Profit/(Loss) from continuing operations	943.17	676.58	0.00	1619.75	0.00	1973.93
10 Profit/(Loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
11 Tax Expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
12 Profit/(Loss) from discontinued operations after tax	0.00	0.00	0.00	0.00	0.00	0.00
13 Profit/ (Loss) for the period	943.17	676.58	0.00	1619.75	0.00	1973.93
14 Other comprehensive Income						
A (i) Items that will not be re-classified to profit/ loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be re-classified to profit/ loss	0.00	0.00	0.00	0.00	0.00	0.00
B (i) Re measurement of post - employment benefit obligations	0.00	0.00	0.00	0.00	0.00	(34.35)
C (i) Items that will be re-classified to profit / loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will be re-classified to profit/ loss	0.00	0.00	0.00	0.00	0.00	0.00
Total Comprehensive Income for the year	943.17	676.58	0.00	1619.75	0.00	1939.58
15 Paid up Equity Share Capital (Face Value of Rs-10/- each)	472.17	472.17	0.00	472.17	0.00	472.17
16 Reserves excluding Revaluation Reserves	0.00	0.00	0.00	0.00	0.00	0.00
17 Earning per Share (EPS) (before & after extra ordinary items)						
- Basic/ Diluted Earning Per Share (Rs.)	19.98	14.33	0.00	34.30	0.00	44.83
A 1) Public Shareholding						
Number of shares	2411277	2411277	0	2411277	0	2411277
Percentage of shareholding	51.07%	51.07%	0.00%	51.07%	0.00%	51.07%
2) Promoters and promoter group shareholding						
a) Pledged/Encumbured						
- Number of shares	-	-	-	-	-	-
- Percentage of shares (as a % of total shareholding of Promoters and Prompter Group)	-	-	-	-	-	-
- Percentage of shares (as a % of total share capital of the Company)	-	-	-	-	-	-
b) Non-encumbered						
- Number of shares	2310385	2310385	0	2310385	0	2310385
- Percentage of shares (as a % of total shareholding of Promoters and Prompter Group)	100%	100%	0	100%	0	100%
- Percentage of shares (as a % of total share capital of the Company)	48.93%	48.93%	0.00%	48.93%	0.00%	48.93%


Registered Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.

Phone No.: 91-22- 4031 8111 Fax: 91-22-4031 8133

Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone No.: +917045957828, +917045957829, +917045957830, +917045956857

E-Mail: business@fredungroup.com Web: www.fredungroup.com



FREDUN PHARMACEUTICALS LIMITED			
Consolidated Statement of Profit and Loss for the Half year Ended 30 Sep, 2025		(Rs. In Lacs.)	
		As at 30 Sept, 2025	As at 31 March, 2025
I	Revenue		
	Revenue from Operations	26,298.82	45,170.65
	Other Operating Revenue	56.73	211.12
	Other income	159.10	125.08
	Total Income	26,514.65	45,506.85
II	Expenses		
	Cost of materials consumed	18,958.38	32,188.89
	Cost of materials consumed for R & D	193.80	209.34
	Changes in inventories of raw materials, packing materials, stock in trade and wip	-224.86	605.00
	Manufacturing & Service Cost	730.04	1,755.54
	Employee benefit Exp.	1,593.27	2,223.12
	Finance Cost	1,426.30	2,237.66
	Depreciation and amortisation expense	331.22	503.94
	Operating and other expenses	1,331.93	3,135.12
	Payment to Auditors	-	18.88
	Impairment loss / (reversal)		
	Total Expenses	24,340.08	42,877.50
III	Profit before exceptional items and tax	2,174.56	2,629.35
	Exceptional Items	-	-
IV	Profit before tax from continuing operations	2,174.56	2,629.35
V	Tax Expenses:		
	Current Tax	554.82	711.58
	Deferred Tax	-	63.85
VI	Profit for the year from continuing operations	1,619.74	1,853.93
VII	Profit before tax from discontinued operations		-
VIII	Tax expenses of discontinued operations	-	-
IX	Profit for the year from discontinued operations		-
X	Net Profit for the year	1,619.74	1,853.93
XI	Other Comprehensive Income		
A	Items that will not be classified to profit and loss		
	i) Re measurement of post - employment benefit obligations	1,619.74	1,939.57
	ii) Income tax related to items that will not be reclassified to profit and loss	-	-
	Profit/Loss for the year attributable to:		
	Owners of the Company	1,619.74	1,939.38
	Non controlling Interests	-0.00	0.19
B	Items that will be reclassified to profit and loss	-	-
XII	Total Comprehensive Income for the year	-	5,733.07
XIII	Earning per equity share (Face value of Rs. 10/- each)		
	Earning per equity share of continuing operations	34.30	44.83
	Basic and diluted (in Rs.)	0.00	0
	Earning per equity share of discontinued operations	0.00	0
	Basic EPS (in Rs.) of continuing and discontinued operations	34.30	44.83
	Diluted Basic EPS (in Rs.) of continuing and discontinued operations	34.30	44.83




Place - Mumbai
Date :- 08.11.2025



For and on behalf of the Board of Directors of Fredun
CIN No - L24239MH1987PLC043662
For Fredun Pharmaceuticals Limited

Dr. (Mrs) Daulat N. Medhora
Joint Managing Director
DIN : 01745277

MR. Fredun N. Medhora
Managing Director & CFO
DIN :01745348

FREDUN PHARMACEUTICALS LIMITED			
Consolidated Balance Sheet for the Half year Ended 30 Sept, 2025		(Rs. in Lacs.)	
		As at 30 Sept, 2025	As at 31 March, 2025
I	ASSETS		
	NON-CURRENT ASSETS		
a)	Property, Plant and Equipment	6,508.82	5,248.93
b)	Capital Work-in-Progress	-	-
c)	Other Intangible Assets	43.99	42.72
d)	Financial assets		
	i) Investments	91.73	75.33
	ii) Loans	-	-
	iii) Other Financial Assets	551.69	379.69
e)	Other Non-current Assets	634.19	198.99
f)	Goodwill	0.00	10.00
	Total non-current assets	7,830.42	5,945.66
	CURRENT ASSETS		
a)	Inventories	22,530.80	23,988.89
b)	Financial Assets		
	i) Investments	75.00	75.00
	ii) Trade and other receivables	6,684.51	17,712.08
	iii) Cash and Cash Equivalents	209.61	63.69
	iv) Bank Balance other than (iii) above	588.30	458.63
	iv) Loans	79.98	46.99
	v) Other Financial Assets	7,644.88	120.29
c)	Other Current Assets	773.96	329.91
	Total current assets	38,587.05	42,795.47
	TOTAL ASSETS	46,417.47	48,741.13
II	EQUITY AND LIABILITIES		
	EQUITY		
a)	Equity share capital	472.17	472.17
b)	Other equity	15,252.70	13,666.10
C)	Non-Controlling Interest	0.01	-
	Total Equity	15,724.89	14,138.26
	LIABILITIES		
	Non-Current Liabilities		
a)	Financial liabilities		
	i) Borrowings	3,022.57	961.30
b)	Provisions	380.50	383.29
c)	Other non-current liabilities	-	0.02
d)	Deferred Tax Liability	448.40	448.40
	Total non-current - liabilities	3,851.47	1,793.01
	Current Liabilities		
a)	Financial liabilities		
	i) Borrowings	14,082.13	15,753.36
	ii) Trade and other payable	9,944.96	14,476.58
	iii) Other financial liabilities	35.80	5.10
b)	Provisions		
c)	Other current liabilities	1,477.08	1,863.23
d)	Current tax liabilities (net)	1,301.14	711.58
	Total current liabilities	26,841.11	32,809.85
	TOTAL EQUITY & LIABILITIES	46,417.47	48,741.13
<div style="display: flex; justify-content: space-between; align-items: flex-start;"> <div style="width: 30%;"> <p>Place - Mumbai Date :- 08.11.2025</p> </div> <div style="width: 30%; text-align: center;">  </div> <div style="width: 30%;"> <p>For and on behalf of the Board of Directors of Fredun Pharmaceuticals Limited CIN No - L24239MH1987PLC043662 For Fredun Pharmaceuticals Limited</p> <div style="display: flex; justify-content: space-around; margin-top: 10px;"> <div style="text-align: center;">  Dr. (Mrs) Daulat N. Medhora Joint Managing Director DIN : 01745277 </div> <div style="text-align: center;">  MR. Fredun N. Medhora Managing Director & CFO DIN :01745348 </div> </div> </div> </div>			

FREDUN PHARMACEUTICALS LIMITED

UNAUDITED CONSOLIDATED CASH FLOW STATEMENT FOR HALF YEAR ENDED 30th Sep, 2025

As at 30th Sept 2025

A) CASH FLOW FROM OPERATING ACTIVITIES:

NET PROFIT AFTER TAXATION	0.00	1,619.74
<u>ADJUSTMENTS FOR :</u>	0.00	0.00
DEPRECIATION	331.22	0.00
INTEREST PAID	1,426.30	0.00
INTEREST RECEIVED	4.49	
CREDITORS WRITTEN BACK	0.00	

1,762.01

3,381.76

ADJUSTMENT TO OPERATING PROFIT

PRIOR PERIOD ADJUSTMENTS

DEFERRED TAX LIABILITY

-34.08

ADJUSTMENT FOR PROPOSED DIVIDEND TAX

ADJUSTMENT FOR TAX PROVISION

OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES

3,347.68

EFFECTS OF CHANGES IN WORKING CAPITAL ITEMS

INCREASE / DECREASE IN :-

INVENTORY	-4,945.43	
INVESTMENTS	52.80	
TRADE RECEIVABLES	4,895.03	
LOANS & ADVANCES	-45.66	
OTHER CURRENT ASSETS	-749.40	
OTHER FINANCIAL ASSETS	-6,777.32	
OTHER FINANCIAL ASSETS	-274.94	
TRADE PAYABLES	3,861.26	
OTHER CURRENT LIABILITIES	453.63	
OTHER NON CURRENT ASSETS	-443.64	
OTHER NON CURRENT INVESTMENTS	-91.45	
OTHER FINANCIAL LIABILITIES	31.96	
SHORT TERM PROVISION	-	
PROVISION FOR TAX	309.86	
RESERVES & SURPLUS	1,086.25	
SHARE PREMIUM (RESERVES & SURPLUS)		-2,637.06

710.62

INCREASE / DECREASE IN :-

LONG TERM LOANS & ADVANCES

LONG TERM PROVISIONS

157.06

157.06

NET CASH FLOW FROM OPERATING ACTIVITIES

867.68

EFFECTS OF CHANGES IN NON CURRENT ITEMS

OTHER NON CURRENT ASSETS

NET ADJUSTED CASH FLOW FROM OPERATING ACTIVITIES

867.68



Dr. [Signature]

FREDUN PHARMACEUTICALS LIMITED

UNAUDITED CONSOLIDATED CASH FLOW STATEMENT FOR HALF YEAR ENDED 30th Sep, 2025

As at 30th Sept 2025

B) CASH FLOW FROM INVESTING ACTIVITIES

PURCHASE OF FIXED ASSETS	-2,073.61	
SALE OF FIXED ASSETS	-	
CAPITAL WORK IN PROGRESS	-	
		-2,073.61
		-1,205.93

C) CASH FLOW FROM FINANCING ACTIVITIES

INCREASE / DECREASE IN ISSUE OF SHARE CAPITAL	-	
INCREASE / DECREASE IN LONG TERM BORROWINGS	1,924.95	
INCREASE / DECREASE IN SHORT TERM BORROWINGS	1,464.48	
INTEREST RECEIVED	-4.49	
INTEREST PAID	-1,426.30	
CREDITORS WRITTEN BACK	-	
		1,958.64
NET INCREASE / DECREASE IN CASH		752.71
OPENING CASH & BANK BALANCE		45.21
CLOSING CASH & BANK BALANCE		797.92

For and on behalf of the Board of Directors of
Fredun Pharmaceuticals Limited

CIN No - L24239MH1987PLC043662

For Fredun Pharmaceuticals Limited

Dr. (Mrs) Daulat N. Medhora

Joint Managing Director
DIN : 01745277



Note:-

- 1 The above Cash Flow Statement has been prepared under the indirect method set out in the Indian Accounting Standard (Ind AS) - 7 on "Statement of Cash Flow".
- 2 Direct taxes paid are treated as arising from operating activities and not bifurcated between investing and financing activities.
- 3 Figures in Bracket sign indicate cash outflow.
- 4 Previous year figures have been regrouped & recast, wherever necessary, to conform to the current year's classification and consolidated cash flow for the Quater ended September, 2025 is for the first time, no comparative financial information has been presented for the previous year.

R.H. Nisar & Co.
Chartered Accountant

501, Krushal Tower, M.G Road, Near Shoppers Stop, Chembur – 400089
Tel no: - 9867351724 Email - rakesh.nisar1@gmail.com

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Fredun Pharmaceuticals Limited,

1. We have reviewed the accompanying statement of consolidated unaudited financial results ('the Statement') of Fredun Pharmaceuticals Limited ('the Parent') and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30th September 2025, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Parent's Board of Directors on 08th November, 2025, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable.

R.H. Nisar & Co.
Chartered Accountant

501, Krushal Tower, M.G Road, Near Shoppers Stop, Chembur – 400089
Tel no: - 9867351724 Email - rakesh.nisar1@gmail.com

4. The statement includes the results of the following entities:

Incorporated in India

- a. Fredun Retail Private Limited
- b. One Pet Stop Private Limited

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR R H NISAR & CO.
CHARTERED ACCOUNTANTS
FIRM'S REGISTRATION NUMBER: 120895W



RAKESH NISAR
PROPRIETOR
MEMBERSHIP NO. 103659
UDIN: 25103659BMODAD1827



PLACE: MUMBAI
DATE: 08.11.2025